XML 73 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition - Drug Discovery (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Deferred revenue $ 949 $ 1,581  
Drug Discovery Services      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Milestone payment yet to be achieved $ 0 350 $ 4,000
Revenue recognized with milestones   $ 350 $ 3,939